Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to provide a preliminary assessment of the safety and effectiveness of
the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the
treatment of chronic hepatitis C virus infection.